Pillar Biosciences said it will supply its oncoReveal Essential+ sequencing assay to a Japan-based liquid biopsy program under LC-SCRUM-Asia, aimed at profiling cfDNA and cfRNA from approximately 2,000 patients with non-small cell lung cancer over two years. The network is led by Japan’s National Cancer Center Hospital East and includes partners across clinical, diagnostic, and pharmaceutical ecosystems. LSI Medience will conduct the testing after validating the assay, positioning the platform for biomarker-driven therapy selection and clinical research. The project’s design ties genomic screening to patient stratification, which can accelerate the match between molecular alterations and emerging precision therapies. For the biotech market, the key operational detail is the dual-analyte approach (cfDNA and cfRNA) and how it will integrate into a national screening and clinical-research network. Companies are likely to monitor readouts around feasibility, turnaround time, and concordance with tissue-based profiling.